Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.39 |
| ▸ | GCKR | Q14397 | 4/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 11/20 | 0.38 |
| ▸ | RXRA | P19793 | 3/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15200884 | 1.00 | GCK (0.39) | GCKGCKRHSD11B1RXRAGRIN1 | |
| SCHEMBL15200965 | 1.00 | GCK (0.39) | GCKGCKRHSD11B1RXRAGRIN1 | |
| SCHEMBL31000265 | 0.79 | GCK (0.46) | GCKGCKRHSD11B1 | |
| SCHEMBL18053748 | 0.79 | GCK (0.46) | GCKGCKRHSD11B1 | |
| SCHEMBL31000262 | 0.79 | GCK (0.46) | GCKGCKRHSD11B1 | |
| SCHEMBL17742 | 0.78 | NR1H2 (0.42) | GCKGCKRJUNNFKB1NFKB2 | |
| SCHEMBL23802503 | 0.78 | JUN (0.36) | JUNNFKB1NFKB2RELA | |
| SCHEMBL1403953 | 0.78 | MEN1 (0.36) | HSD11B1RXRAGRIN1GRIN2BJUN | |
| SCHEMBL31002408 | 0.78 | JUN (0.36) | HSD11B1JUNNFKB1NFKB2RELA | |
| SCHEMBL15201125 | 0.77 | GCK (0.44) | GCKGCKRHSD11B1RXRAGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071488-B | Substituted 1,2, 3-triazoles as NR 2B-selective NMDA modulators | 詹森药业有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-08 | — | — | US | disclosed |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-09 | — | — | US | disclosed |
| US-10233173-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-19 | — | — | US | disclosed |
| EP-3414233-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-12-19 | — | — | EP | disclosed |
| US-20180334451-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-22 | — | — | US | disclosed |
| US-10071988-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-11 | — | — | US | disclosed |
| WO-2017139428-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | WO | disclosed |
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-10 | — | — | US | disclosed |
| WO-2013123444-A1 | SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013123444-A1 | SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334451-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | GCK 3654/4885GCKR 2904/4885HSD11B1 1970/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | GCK 2/4885GCKR 1/4885HSD11B1 1443/4885 |
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | GCK 3654/4885GCKR 2904/4885HSD11B1 1970/4885 |
| US-10233173-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | GCK 3654/4885GCKR 2904/4885HSD11B1 1970/4885 |
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | GCK 3654/4885GCKR 2904/4885HSD11B1 1970/4885 |
| US-10071988-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | GCK 3654/4885GCKR 2904/4885HSD11B1 1970/4885 |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | GCK 3654/4885GCKR 2904/4885HSD11B1 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.